# Debate Transcript — 2026-07-18-4d-molecular-amd-data

PAPER-TRADING SIMULATION ONLY. NOT FINANCIAL ADVICE.

Strategy: three-round-panel (debate-three-round-panel). Personas: bull (sonnet), bear
(sonnet), quant (opus). Synthesizer: opus. Relevant institutional lessons queried via
`toa lessons-relevant --type product --tickers FDMT`: none found.

Market data anchor: FDMT $11.30 at 2026-07-22T15:30:00Z
(source: https://api.twelvedata.com/time_series?symbol=FDMT&interval=1min&date=2026-07-22&timezone=UTC).
Today (2026-07-22) is T+4 calendar days / T+2 trading days after the 2026-07-18 event.

## Round 1 — Independent research

### Bull (confidence 35/100)
Bullish on mechanism — large anti-VEGF injection-burden market, 4D-150 seen as
best-positioned ocular gene therapy asset; a clean 2-year durability readout (efficacy
holding, no new inflammation signal) would de-risk the pivotal 4FRONT-1 thesis.
Explicitly flying blind on the actual PRISM data content and on the July 18-19 price
reaction direction — flagged as the biggest gap in the thesis. Proposed: long common
shares, only after confirming the intraday/T+1 reaction was positive and holding;
2-6 week swing; hard stop below the pre-event low.

### Bear (confidence 15/100)
Catalyst is 4 trading days stale — the $11.30 print already reflects whatever the
market's read of the data was; no informational edge unless the market misread it.
Risks: AAV ocular gene therapy durability decay year 1 → year 2, intraocular
inflammation safety overhang, 4FRONT-1 timeline/execution risk, thin small-cap
liquidity/gap risk. Would change mind: a post-7/18 analyst note with stated rationale,
elevated options IV/skew persisting days later, or unexplained peer divergence vs.
Adverum/RegenxBio.

### Quant (confidence 12/100)
T+2 trading days since the catalyst — edge essentially gone; base rate is ~85-90% of a
binary biotech catalyst move realized T0, with a small, noisy PEAD-like drift of
10-15% of the initial move over T+1 to T+5. Explicit EV calc: P(favorable
drift)=0.52, ±3% payoff → gross EV +0.12%, minus ~0.6% round-trip
costs/spread = **net EV -0.48%**. Even P=0.55 stays net-negative. Recommends sizing
zero absent a genuinely differentiated forward thesis (e.g. 4FRONT-1 timing
specifically, not the print).

## Round 2 — Rebuttal

### Bull (revised confidence 15/100)
Concedes quant's EV math kills the pure "trade the print" thesis — no rebuttal to the
arithmetic. Never independently verified the "reaction confirmed positive and
holding" contingency, so can't size on it. Residual bull case survives only if
$11.30 is still below pre-print levels despite genuinely clean data (an unverified
disconnect) or a dated 4FRONT-1 timeline lands inside a 2-6 week hold — neither
confirmed.

### Bear (revised confidence 10/100)
Bull's contingency relocates the objection rather than solving it: if the reaction was
positive and is still holding, that's already priced in (no edge); if it wasn't
positive, there's no thesis. Adopts quant's EV framing as the quantitative backbone.
Concedes a confirmed, durable move would be weak evidence against a fade/overhang
thesis, but no one at the table has the actual reaction data, options IV, or a
forward-dated 4FRONT-1 catalyst.

### Quant (revised confidence 15/100, "confidence in the no-trade call")
Bull's contingency doesn't lift P(favorable drift) above ~0.52 — if anything it raises
entry price and worsens risk/reward by waiting for confirmation. EV math unchanged:
net -0.48%, hold. The only place edge could live is a forward 4FRONT-1
timing/probability-of-success-revision thesis, but it's unquantified by everyone (no
readout date, no options term structure) — flagged as a research task, not a
tradeable position today. Final: size ZERO on the print.

## Round 3 — Synthesis

**Hypothesis:** The 4D-150 2-year PRISM readout is a spent catalyst. At T+2 trading
days with no confirmed reaction anchor, no options IV/skew, no analyst repricing, and
no dated 4FRONT-1 forward catalyst inside the horizon, no participant produced a
differentiated, quantifiable edge. The pure "trade the print" thesis is EV-negative
after costs; the only surviving bull kernel is an unverified price/data disconnect
that no one could confirm.

- Direction: no-trade
- Confidence: 82 (high confidence in the no-trade call, not in any directional view)

**Plan:** FDMT — action: none/skip, do not enter. Research task (not a position):
establish the 4FRONT-1 pivotal readout/enrollment-completion date and pull FDMT
options term structure + skew; if a dated catalyst lands inside a tradeable window
with a probability-of-success-revision thesis, re-open as a *new* opportunity rather
than retrofitting it onto this stale print.

**Dissent (gold for post-mortem):** The unverified $11.30-vs-pre-print disconnect. If
the 2-year data was genuinely clean and price is still at/below pre-event levels, the
panel defaulted to "no anchor = no trade" and may have passed on a real long. Bear/
quant counter that an unmeasured disconnect is indistinguishable from no edge and
acting on it would be gambling, not sizing.

**Rationale:** All three seats independently converged on zero size, and both bull and
bear explicitly adopted quant's EV framework — a genuine consensus, not manufactured
balance. Every candidate edge either already played out (no remaining drift) or
remains unquantified (a research question, not a trade).
